Celldex Therapeutics reported topline results from the ongoing Phase 2 study of barzolvolimab in EoE.
Study focused on mast cell depletion in EoE with barzolvolimab.
Results showed profound mast cell reduction but no improvement in EoE symptoms.
Primary Endpoint Met
Barzolvolimab successfully depleted mast cells in the gastrointestinal tract.
Clinical Outcome Disappointing
Profound mast cell depletion did not improve EoE symptoms.
Future Development Plans
Celldex will not advance in EoE but supports KIT- or SCF-targeted therapies in GI indications.
- Despite successful mast cell depletion, no clinical improvement in EoE symptoms was observed.
- Safety profile of barzolvolimab at 300 mg Q4 weekly dosing regimen remains favorable.
- Results support future development in other GI indications where mast cells are key players.
Celldex remains focused on advancing the pipeline for barzolvolimab in other indications with promising ongoing studies.